Trials / Completed
CompletedNCT01889277
Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy
A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 in Subjects With Diabetic Nephropathy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of MT-3995 in Subjects with Diabetic Nephropathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-3995-Low | |
| DRUG | MT-3995-High | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2013-06-28
- Last updated
- 2015-01-27
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01889277. Inclusion in this directory is not an endorsement.